trimetazidine / Generic mfg. - LARVOL DELTA

A randomized, open-label study of the efficacy of trimetazidine in preventing acute myocardial injury in patients hospitalized for moderate to severe acute respiratory syndrome caused by SARS-CoV-2 (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

Novel chiral borneol derivatives as potential cardioprotective agents: Design, synthesis and biological evaluation. (PubMed, Bioorg Chem) - "The thalidomide incident has aroused our attention immensely to the structure activity relationship of chiral drugs...It has the same 2,3,4-trimethoxybenzene structure as the first-line anti-myocardial ischemia drug, trimetazidine...Furthermore, in vivo results showed that compound 19 could obviously reduce myocardial infarct size, prevent excessive release of cTn1, inhibit oxidative stress injury and improve cardiac ultrastructure in MI/R rats. The present study provided new potential myocardial protectant from borneol derivatives for clinical treatment of MI/R injury."

Journal • Cardiovascular • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury • IL18

In Vitro Metabolism of Doping Agents (Stanozolol, LGD-4033, Anastrozole, GW1516, Trimetazidine) by Human Seminal Vesicle and Liver Fractions. (PubMed, Metabolites) - "Gene expression and enzymatic activity in CYP3A4 and CYP1A2-major hepatic enzymes-were absent in SV-S9. Overall, these pilot study results suggest that the seminal vesicle has only a low capacity for xenobiotic metabolism, which translates into a limited role in the biotransformation of drugs and, hence, the metabolic pattern."

Journal • Preclinical • CYP1A2 • CYP2C9 • CYP2E1 • CYP3A4

Metoprolol and Trimetazidine for Coronary Heart Disease With Angina (clinicaltrials.gov) - P=N/A | N=102 | Completed | Sponsor: Shiyan City Renmin Hospital

Biomarker • New trial • Cardiovascular • Coronary Artery Disease • Heart Failure

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis. (PubMed, Cardiooncology) - "Trimetazidine, ACEI/ARB, beta-blocker, dexrazoxane, and MRA demonstrate potential as cardioprotective agents in breast cancer patients undergoing anthracycline chemotherapy. Further research is needed to elucidate the specific cardioprotective mechanisms against anthracycline-induced cardiotoxicity."

Journal • Retrospective data • Review • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. (PubMed, Cardiovasc Res) - "The ENERGY trial is the first proof-of-concept randomized controlled trial to test the hypothesis that TMZ improves MEE in MYBPC3 or MYH7 PV/LPV carriers. We conclude that metabolic therapy with TMZ may not correct the P/LP gene variant-related decrease in MEE."

Clinical • Journal • Preclinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • MYH7

Trimetazidine stimulates intracellular Ca2+ transients and zebrafish locomotor activity in spinal neurons. (PubMed, Sci Rep) - "Even though elevated intracellular Ca2+ levels have often been associated to neurotoxicity, it is unclear if the neuronal excitability features in some neuro-muscular disorders are compensatory or pathological. Therefore, this newly reported effect of TMZ which transiently and selectively enhances spinal neuron firing deserves to be further detailed and taken into account when the possible repurposing of this drug is proposed for the treatment of neuro-muscular disorders."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Sarcopenia • NEUROD1

Treatment Modalities for Angina with Non-Obstructive Coronary Arteries (ANOCA): A Systematic Review and Meta-Analysis. (PubMed, J Clin Med) - "Angina pectoris frequency improved significantly in the majority of the treatment modalities, with neuromodulation resulting in -3.35 standardised mean difference (SMD) (95% CI: -5.13; -1.56), trimetazidine in -1.74 SMD (-2.63; -0.85), traditional Chinese medicine in -1.55 SMD (-2.36; -0.75), beta-blockers in -1.32 SMD (-1.88; -0.77), enhanced external counterpulsation in -1.27 SMD (-2.04; -0.49), stem cell therapy in -1.04 SMD (-1.51; -0.57), lifestyle interventions in -0.86 SMD (-1.15; -0.57), RAAS-inhibitors in -0.83 SMD (-1.31; -0.35) and calcium channel blockers in -0.64 SMD (-0.92; -0.35)...However, these results should be interpreted cautiously, as only ten of the studies included in the meta-analysis meet the current definition of ANOCA. This review underlines the importance of undertaking new studies with existing treatment modalities to determine the efficacy in patients with ANOCA."

Journal • Retrospective data • Review • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Yangxinshi tablet protects against myocardial injury and increases skeletal muscle exercise capacity by regulating mitochondrial bioenergetics. (PubMed, Phytomedicine) - "This study revealed that YXST improved cardiac function and exercise tolerance in I/R mice, particularly we found that YXST could directly enhance the exercise capacity of mice under normal condition. Mechanismly, YXST significantly regulated mitochondrial biogenesis, oxidative phosphorylation and myokine production in vivo and in vitro. Our findings provide novel mechanistic insights and pharmacological basis for the application of YXST against coronary heart disease and skeletal muscle injury."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Inflammation • Myocardial Ischemia • Reperfusion Injury • BACH1 • BRIP1

Effects of trimetazidine on cardiac function and ventricular remodeling in patients with ischemic cardiomyopathy: a systematic review and meta-analysis. (PubMed, Gen Thorac Cardiovasc Surg) - "TMZ can effectively improve cardiac function in patients with ischemic cardiomyopathy, but its impact on ventricular remodeling is limited. Future research should further explore its application in the treatment of ICM."

Journal • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Coronary Artery Disease

Nutrient-Driven Antioxidant Interventions for Prevention of Age-Related and Diabetic Cataracts. (PubMed, Nutrients) - "Agents such as trimetazidine, Moringa oleifera stem extract, ginsenoside Rg1, lanosterol nanoparticles, β-casomorphin-7, and cerium oxide-based nanotherapies have been shown to mitigate oxidative damage, modulate redox signaling pathways, and preserve lens clarity. Advances in drug delivery, including topical formulations, nanoparticle carriers, and intravitreal injections, have been proposed to overcome the anatomical and pharmacokinetic barriers associated with the avascular lens. The new data support ongoing translational research to maximize the clinical use of antioxidants and highlight their therapeutic potential in the prevention of age-related and diabetic cataracts."

Journal • Review • Cataract • Ophthalmology

TRI-ME: Trimetazidine to treat Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A double-blind, randomised, placebo-controlled efficacy trial (ANZCTR) - P2/3 | N=126 | Recruiting | Sponsor: Deakin University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Fatigue • Infectious Disease

Efficacy of trimetazidine for myocardial ischemia-reperfusion injury in rat models: a systematic review and meta-analysis. (PubMed, PeerJ) - "TMZ can attenuate the damage caused by MIRI in rat, with a myocardial protective effect. These findings would facilitate preclinical evidence for further investigation."

Clinical • Journal • Preclinical • Retrospective data • Review • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury

No fault or negligence after an adverse analytical finding due to a contaminated supplement: mission impossible. Two examples involving trimetazidine. (PubMed, Clin Chem Lab Med) - "From a forensic perspective, contamination is not doping. To avoid these conflicting issues with contaminations, the debate should move to the interest of using hair test results and the need of implementing a threshold for reporting the presence of a drug in urine at very low concentration."

Journal

The Antioxidant Properties and Cardiovascular, Antidiabetic, and Renal Effects of Trimetazidine Described in Research on Experimental Models. (PubMed, Curr Rev Clin Exp Pharmacol) - "The information compiled in this review shows that trimetazidine is effective in reducing damage associated with oxidative stress, as evaluated in different experimental models. The cardioprotective and nephroprotective effects of this drug have been demonstrated in ischemic and non-ischemic models."

Journal • Review • Cardiovascular • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Renal Disease

Beyond Angina: Unlocking the Multifaceted Therapeutic Potential of Trimetazidine. (PubMed, Curr Rev Clin Exp Pharmacol) - No abstract available

Journal • Cardiovascular

Chondrocyte fatty acid oxidation drives osteoarthritis via SOX9 degradation and epigenetic regulation. (PubMed, Nat Commun) - "Cartilage-targeted delivery of trimetazidine, an FAO inhibitor and AMPK activator, demonstrates superior efficacy in a mouse model of metabolism-associated post-traumatic osteoarthritis. These findings suggest that targeting chondrocyte-lipid metabolism may offer new therapeutic strategies for osteoarthritis."

Journal • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Osteoarthritis • Pain • Rheumatology • Targeted Protein Degradation • MMP13 • SOX9

Trimetazidine improves dexamethasone-induced insulin resistance and associated hepatic abnormalities in rats. (PubMed, Life Sci) - "This study demonstrated that TMZ significantly improved DEXA-induced hepatic alterations by modulating the HMGB1/p-JAK1/p-STAT3/NF-κB pathway in liver. Our findings provide new evidence supporting the application of TMZ for treating DEXA-induced IR and hepatic steatosis."

IO biomarker • Journal • Preclinical • B Cell Lymphoma • Hepatology • Lymphoma • Metabolic Disorders • Oncology • BCL2 • CASP3 • HMGB1 • IL6 • JAK1

TIDE (Trimetazidine in bipolar depression): A double-blind, randomised, placebo-controlled trial (ANZCTR) - P3 | N=260 | Recruiting | Sponsor: Deakin University | Not yet recruiting ➔ Recruiting | Phase classification: P2 ➔ P3

Enrollment open • Phase classification • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Combination of antioxidants and targeted temperature management ameliorates post-cardiac arrest syndrome in a rat model of asphyxial cardiac arrest. (PubMed, Shock) - "Combining antioxidants with TTM alleviates PCAS and improves outcomes by reducing reactive oxygen species levels and mitigating myocardial and cerebral pathological injury."

Journal • Preclinical • Cardiovascular

Coronary microcirculation dysfunction causing ischemia with non-obstructive coronary arteries: a case report. (PubMed, Front Cardiovasc Med) - "After six months of targeted treatment with nicorandil, coenzyme Q10, trimetazidine, and rosuvastatin, the patient's symptoms resolved, and myocardial ischemia reversed. The NOTCH1 gene may play a potential role in INOCA caused by CMVD, however, further research is needed to elucidate its underlying regulatory mechanisms. The findings provide a foundation for precise diagnosis and personalized management of INOCA."

Journal • Cardiomyopathy • Cardiovascular • Myocardial Ischemia • MYH7 • NOTCH1

Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study. (PubMed, Cardiol Ther) - P | "These data support the symptomatic benefits and good tolerability associated with adding trimetazidine MR 80 mg OD to other antianginal therapies in patients with persistent symptoms. Graphical abstract available for this article."

Journal • Observational data • Cardiovascular

Effects of Trimetazidine Combined with Atorvastatin on Cardiac Function in Patients with Stable Angina Pectoris of Coronary Heart Disease. (PubMed, Int J Gen Med) - "The trimetazidine-atorvastatin combination demonstrates synergistic effects in improving angina symptoms, lipid metabolism, and cardiac function in stable CHD, with additional benefits in endothelial protection and measured inflammatory regulation. These findings support its consideration as adjunctive therapy, though further validation of broader inflammatory impacts is warranted."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Inflammation • Metabolic Disorders • Pain • CRP • TNFA

MAFLD: Benefits of Trimetazidine in MASLD Patients (clinicaltrials.gov) - P2 | N=60 | Completed | Sponsor: October 6 University | Recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Nov 2024

Trial completion • Trial completion date • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease

Trimetazidine effect on kidney function in patients undergoing coronary procedures. (PubMed, BMC Pharmacol Toxicol) - "Our Cohort Observational Single-Center study showed that TMZ did not provide robust protection against CIN at 72 h. However, TMZ may offer a modest, clinically relevant, longer-term renal benefit at one month in patients undergoing elective coronary procedures. Further randomized trials are warranted to validate TMZ's efficacy and explore its mechanisms."

Journal • Renal Disease